Published in Vaccine Weekly, March 20th, 1995
The topic was especially timely because just a week earlier the U.S. Food and Drug Administration (FDA) had licensed SmithKline Beecham Biologicals (Philadelphia, Pennsylvania) to market Havrix, (hepatitis A vaccine, inactivated) the company's hepatitis A vaccine.
"Hemophiliac patients are at risk for hepatitis A. We don't know the extent of that risk," stated Bruce Evatt, M.D., chief, Hematologic Diseases Branch, U.S. Centers for Disease Control and Prevention (CDC), one of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly